Austrian Breast & Colorectal Cancer Study Group
Quick facts
Phase 3 pipeline
- Fluorouracil implant · Oncology
Fluorouracil implant delivers the chemotherapy agent 5-fluorouracil directly to tumor tissue to inhibit thymidylate synthase and disrupt DNA synthesis in cancer cells. - Tamoxifen alone · Oncology
Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks estrogen binding to its receptor on breast cancer cells, inhibiting their growth. - Tamoxifen + Aminoglutethimide · Oncology
Tamoxifen acts as a selective estrogen receptor modulator (SERM) to inhibit estrogen's action in breast tissue, while aminoglutethimide inhibits the enzyme CYP11A1, which is involved in the synthesis of steroids, including estrogen.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Austrian Breast & Colorectal Cancer Study Group portfolio CI brief
- Austrian Breast & Colorectal Cancer Study Group pipeline updates RSS
Frequently asked questions about Austrian Breast & Colorectal Cancer Study Group
What is Austrian Breast & Colorectal Cancer Study Group's pipeline?
Austrian Breast & Colorectal Cancer Study Group has 3 drugs in Phase 3, 2 in Phase 2, 0 in Phase 1. Late-stage candidates include Fluorouracil implant, Tamoxifen alone, Tamoxifen + Aminoglutethimide.
Related
- Sector hub: All tracked pharma companies